Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Dimitrios Diamandidis

Hematology & Oncology Las Vegas, NV Medical Doctor

NPI 1063457737 CMS profile 230046

2650 N Tenaya Way Ste 201, Las Vegas, NV 89128

Open in the dashboard

General payments

$17,643

680 records reported · program years 2019–2024

Research payments

$1,500

Paid to them · 2 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Dimitrios Diamandidis of Las Vegas, NV is reported in the CMS Open Payments database as having received $17,643 across 680 general payments and $1,500 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $205 4
2023 General $6,020 192
2022 General $4,870 222
2022 Research $1,500 2
2021 General $4,164 160
2020 General $1,643 83
2019 General $743 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dimitrios Diamandidis
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Dimitrios Diamandidis were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Dimitrios Diamandidis Hematology & Oncology median Middle half National median
2019 $743 $529 $121–$2,516 $163
2020 $1,643 $339 $82–$2,213 $114
2021 $4,164 $263 $49–$1,965 $132
2022 $4,870 $416 $103–$2,395 $149
2023 $6,020 $542 $125–$2,646 $160
2024 $205 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Eisai Inc. $1,909 30 payments
  2. Novartis Pharmaceuticals Corporation $1,715 48 payments
  3. AstraZeneca Pharmaceuticals LP $1,336 40 payments
  4. Astellas Pharma US Inc $1,005 35 payments
  5. Incyte Corporation $1,001 33 payments
  6. Amgen Inc. $803 33 payments
  7. Janssen Biotech, Inc. $599 29 payments
  8. EMD Serono, Inc. $508 26 payments
  9. GlaxoSmithKline, LLC. $441 22 payments
  10. Alexion Pharmaceuticals, Inc. $393 21 payments
  11. Other $7,933 363 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $13,375 641 payments
  2. Education $1,722 25 payments
  3. Consulting Fee $1,365 1 payment
  4. Long term medical supply or device loan $1,182 13 payments
Products named General payments · program years 2019–2024
  1. Lenvima $1,909 30 payments
  2. KISQALI $982 12 payments
  3. JAKAFI $552 23 payments
  4. TAGRISSO $526 13 payments
  5. CALQUENCE $467 13 payments
  6. ZEJULA $359 19 payments
  7. BRUKINSA $343 13 payments
  8. ULTOMIRIS $332 18 payments
  9. REBLOZYL $325 9 payments
  10. KEYTRUDA $316 17 payments
  11. Other $11,798 586 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Onquality Pharmaceuticals USA LLC $1,500 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

68

Median for Medical Oncology: 414

Drug cost

$11,390

Median for Medical Oncology: $849,427

Branded share of claims

19.1%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $10,726
Letrozole Generic 41 $501
Anastrozole Generic 14 $164

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $167
$167 — —
Voranigo
  • Servier Pharmaceuticals LLC $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

682 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record